Gene therapy trial aims to fix heart muscle in rare genetic disease
Disease control
Recruiting now
This early-stage trial tests a single dose of a gene therapy called NVC-001 in 21 adults with a genetic form of dilated cardiomyopathy (LMNA mutation). The therapy uses a harmless virus to deliver a modified gene into heart cells, aiming to protect the heart muscle. The main goal…
Phase: PHASE1, PHASE2 • Sponsor: Nuevocor Pte. Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC